4basebio (LON:4BB) Stock Price Down 2.2% – Here’s Why

4basebio PLC (LON:4BB) was down 2.2% during trading on Thursday . The company traded as low as GBX 450 and last traded at GBX 450. 1,291 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 1,349 shares. The stock had previously closed at GBX 460.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reduced their price target on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating for the company in a research report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, 4basebio currently has an average rating of “Buy” and a consensus price target of GBX 1,400.

4basebio Stock Up 4.3%

The business has a 50 day moving average of GBX 519.47 and a 200-day moving average of GBX 517.99. The stock has a market cap of £75.10 million, a PE ratio of -4.45 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47.

4basebio (LON:4BB) last released its quarterly earnings results on Wednesday, May 20th. The company reported GBX (1.09) EPS for the quarter. The business had revenue of GBX 169 million during the quarter. Equities research analysts predict that 4basebio PLC will post -3.43 EPS for the current fiscal year.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.